Emovi

About Emovi

Emovi, a medical device company established in 2007 and headquartered in Laval, Quebec, focuses on providing advanced solutions for knee joint assessment. The company was founded by Michelle Laflamme, who serves as President and CEO. An experienced entrepreneur and lawyer with a Master's degree in law and biotechnology, Laflamme was working as a business advisor for the development of the KneeKG system when she recognized its potential and acquired the intellectual property in 2008 to form Emovi. She was joined by Alex Fuentes, a researcher with a Ph.D. in biomechanics who was part of the original team that developed the device.

The company’s core product is the KneeKG, a system designed to perform a 'Knee Kinesiography'. This examination provides a dynamic, 3D assessment of the knee while it is in motion and bearing weight, typically as the patient walks on a treadmill. In contrast to static imaging like X-rays or MRIs, the KneeKG captures data on the knee's biomechanics, including flexion/extension, varus/valgus, and tibial rotation, to identify the functional causes of pain. This approach is likened to an EKG for the heart, offering objective, quantifiable data on the joint's function to help clinicians diagnose conditions such as knee osteoarthritis, ligament and meniscus injuries, and patellofemoral pain syndrome.

Emovi's business model operates on a Software as a Service (SaaS) basis, where healthcare providers in clinics and hospitals utilize the KneeKG system. The company generates revenue by monitoring the usage of the device and billing clients accordingly. The system is intended for use by orthopedic surgeons, physical therapists, and other healthcare professionals to create personalized and targeted treatment plans. The data gathered helps in determining the appropriateness of surgery, guiding non-surgical interventions, and monitoring patient progress. Emovi has received regulatory clearances for the KneeKG, including from the FDA (510k), Health Canada, and CE Marking in Europe, allowing for its commercialization in these markets. The company has secured significant funding, including a Series C round, and has been supported by investors such as TVM Capital, Desjardins, and the Quebec government.